Key Points: Question: Among sodium-glucose cotransporter 2 (SGLT2) inhibitors, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, and sulfonylureas, which class of oral antidiabetic drugs (OADs) is the preferred therapeutic option for patients with both nonalcohol...
Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled tria... pmhdev - 《Centre for Reviews & Dissemination》 被引量: 8发表: 2012年 Assessment of baseline characteristics, glycemic control and oral...
Recently, LANCL2 is a target for the binding and signaling of abscisic acid (ABA), a plant hormone with anti-diabetic and anti-inflammatory effects. The goal of this study was to determine the role of LANCL2 as a potential therapeutic target for developing novel drugs and nutraceuticals ...
We first compared the BPV parameters of patients receiving a given antihypertensive drug class of interest (regardless of the concomitant prescrip- tion of other drugs) with those of patients not treated with that class, but receiving any other type of antihypertensive drugs (control group). ...
We studied exercise training combined with the use of antihypertensive drugs and examined the following questions. (1) Are there additive antihypertensive ... MH Kelemen - 《Jama》 被引量: 139发表: 1990年 Are there benefits to specific antihypertensive drug therapy? The antihypertensive drug classes...
Applications based on AREs are employed to detect and monitor chemicals/drugs. • Computational methods and analysis of AREs are still in its infancy. Abstract Exposure to antioxidants and xenobiotics triggers the expression of a myriad of genes encoding antioxidant proteins, detoxifying enzymes, and...
Tramadol (Ultram) and tapentadol (Nucynta) are what class of drugs? A- Partial agonists B- Opioid antagonists C- Non-steroidal anti-inflammatory drugs D- Non-conventional opioid agonist Febrile seizure is reported with code Compare and contrast cerebral concussion and cerebral contusion. Pro...
Several MCHR1 antagonists were presented in the last decade; some of them have entered clinical trials for the treatment of obesity,23 some are in discussion of becoming anti-diabetic drugs.24 However, to enable confidence in preclinical to clinical translation of central MCHR1 pharmacology, a ...
This review provides an overview of the current literature and sheds light on the modes of action of novel antidiabetic drugs, focusing on inflammation, oxidative stress, and fibrosis. Keywords: diabetes; cardioprotection; SGLT2 inhibitor; GLP-1 receptor agonist; DPP-4 inhibitor; inflammation; ...
The compound is also under development for the treatment of diabetic foot infection, for which the company has finished one Phase II clinical trial [16]. Antibiotics 2013, 2 510 Ferrer Internacional has completed one Phase III clinical trial to evaluate the topical formulation of ozenoxacin in ...